FDA Approves Ultomiris (ravulizumab-cwvz) for Generalized Myasthenia Gravis
The FDA has approved Ultomiris (ravulizumab-cwvz) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Ultomiris is a complement inhibitor that works by blocking complement-mediated damage at the neuromuscular junction. This approval provides a new treatment option for patients with AChR antibody-positive gMG, a chronic autoimmune disease characterized by fluctuating muscle weakness. The approval was based on clinical trial data demonstrating efficacy and safety, though specific trial outcomes are not detailed in the prescribing information. Clinicians should note that Ultomiris is administered as an intravenous infusion with weight-based dosing every 8 weeks after a loading dose.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Ultomiris (ravulizumab-cwvz) is a complement inhibitor. It binds to complement protein C5, inhibiting its cleavage to C5a and C5b, thereby preventing terminal complement-mediated cell damage.
Ultomiris is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. It is also indicated for other conditions including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in adult and pediatric patients one month of age and older, and neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody-positive adults.
Ultomiris is administered as an intravenous infusion. For gMG, the recommended dosing is weight-based: for patients 40 kg to less than 60 kg, a loading dose of 2400 mg followed by 3000 mg every 8 weeks; for 60 kg to less than 100 kg, 2700 mg loading then 3300 mg every 8 weeks; for 100 kg or greater, 3000 mg loading then 3600 mg every 8 weeks. The first maintenance dose is given 2 weeks after the loading dose. Dosing may vary within 7 days of scheduled infusion. Supplemental doses are required after plasma exchange, plasmapheresis, or intravenous immunoglobulin. Vaccination against meningococcal infection is required at least 2 weeks prior to initiation, and prescribers must enroll in the ULTOMIRIS and SOLIRIS REMS.
Trial data not available in label.
Ultomiris is contraindicated in patients with unresolved serious meningococcal infection. Vaccination against meningococcal serogroups A, C, W, Y and B is required at least 2 weeks before starting treatment. If urgent therapy is needed, antibacterial prophylaxis should be given and vaccines administered as soon as possible. Ultomiris is not indicated for Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS).
Ultomiris provides a treatment option for adult patients with anti-AChR antibody-positive gMG. As a complement inhibitor, it offers a mechanism distinct from other therapies. Its place in therapy relative to other treatments is not specified in the label.
View Original Abstract ↓
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients
Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
Related in Hematology
From Other Specialties
